Driehaus Capital Management LLC Invests $4.11 Million in Immunome, Inc. $IMNM

Key Points

• Driehaus Capital Management LLC acquired a new stake in Immunome, Inc., purchasing 610,551 shares valued at approximately $4.11 million, representing about 0.70% ownership.
• Immunome reported better-than-expected earnings, with a quarterly loss of ($0.50) per share, exceeding the consensus estimate of ($0.52), alongside a revenue of $4.02 million.
• Analysts have mixed ratings on Immunome, with several firms adjusting their price targets, and an average target of $22.50, indicating a generally positive outlook.

Driehaus Capital Management LLC bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 610,551 shares of the company's stock, valued at approximately $4,109,000. Driehaus Capital Management LLC owned approximately 0.70% of Immunome as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Immunome in the fourth quarter worth $70,000. Tower Research Capital LLC TRC raised its stake in shares of Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Immunome during the fourth quarter valued at about $95,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Immunome during the first quarter valued at about $95,000. Finally, KLP Kapitalforvaltning AS increased its position in shares of Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock valued at $115,000 after buying an additional 10,000 shares during the period. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Trading Up 5.4%

IMNM traded up $0.53 on Friday, reaching $10.33. The stock had a trading volume of 763,514 shares, compared to its average volume of 985,862. The company has a market cap of $899.12 million, a P/E ratio of -3.35 and a beta of 1.92. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.73. The business's 50-day moving average price is $9.85 and its two-hundred day moving average price is $8.85.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. The business had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. As a group, analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on IMNM. Craig Hallum began coverage on shares of Immunome in a report on Friday. They issued a "buy" rating and a $26.00 target price on the stock. Guggenheim restated a "buy" rating and issued a $25.00 target price on shares of Immunome in a report on Monday, August 25th. Evercore ISI initiated coverage on Immunome in a research note on Friday, August 22nd. They issued an "outperform" rating and a $18.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Nine analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $22.89.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.